Analysts rave over Biogen MS pill on second Phase III successPharma TimesDr O'Neill also highlighted the promise being shown by PEG-Avonex and Abbott-partnered daclizumab, both of which are expected to report Phase III data in 2013. The company is …
Biogen Idec, Abbott present efficacy data of DAC HYP in RRMS treatmentPharmaceutical Business ReviewBiogen Idec and Abbott have reported the additional results from the Select Phase 2b trial, which assessed the investigational compound daclizumab high-…
Proactive Investors USA & CanadaBiogen Idec (BIIB) Shares Given New $127.00 Price Target by Oppenheimer (OPY …LocalizedUSAIt includes BG-12, Daclizumab, Fampridine, GA101, Humanized Anti-CD20 MAb (ocrelizumab), Lixiavaptan, Long-Acting rFactor IX and…
Kidney Graft Loss Due to BK Virus Need Not Prevent RetransplantationRenal and Urology NewsHowever, replacing alemtuzumab with basiliximab may be necessary to achieve optimal outcomes in retransplanted patients, according to data presented at the Infect…
Abbott Labs: Genes Aren't The Only Thing That Can Effectively Be SplicedSeeking AlphaOne such drug is Daclizumab. Abbott just reported positive Phase 2b trial results for the drug in treating multiple sclerosis. Patients enrolled in the study saw u…
Abbott, Biogen report MS drug reduced relapse rateBusinessWeekBiogen Idec and Abbott Laboratories said Sunday a mid-stage study of their multiple sclerosis medicine daclizumab showed that the experimental drug worked better than placebo at preventing r…
Weekly Update: Market Volatility Directs to Greater Volumes for NYSE EuronextGalaxy StocksAbbott Laboratories Inc. (NYSE:ABT) on Saturday reported constructive data from a trial to assess an investigational compound called daclizumab high-yield process…
Abbott, Biogen report MS drug reduced relapse rateBoston.comBiogen Idec and Abbott Laboratories said Sunday a mid-stage study of their multiple sclerosis medicine daclizumab showed that the experimental drug worked better than placebo at preventing rel…
Stocks to watch Monday: Mattel, Biogen IdecMarketWatchMore good news for Biogen Idec Inc.: The company and Abbott Laboratories Inc. /quotes/zigman/216393/quotes/nls/abt ABT -0.76% on Saturday presented positive data from a trial to evaluate an investig…
Biogen jumps on strong MS drug data: Sanofi's Lemtrada significant improvement …The Pharma LetterBiogen and partner Abbott Laboratories (NYSE: ABT) also announced additional results from the SELECT Phase IIb trial, the first of two registrational…